Placebo (SC)

DRUG6 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, Janssen-Cilag Ltd., Astria Therapeutics, Inc., Generate Biomedicines

Conditions

AsthmaCOPD (Chronic Obstructive Pulmonary Disease)Crohn DiseaseDengueHealthyHereditary Angioedema

Phase 1

Tetravalent Chimeric Dengue Vaccine Trial

CompletedNCT01110551

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2010-05-31End: 2012-12-31Updated: 2013-02-04

A Study of LY3200327 in Healthy Participants

CompletedNCT02595736

Eli Lilly and CompanyHealthy

Start: 2015-11-30End: 2016-08-31Updated: 2016-09-12

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

CompletedNCT05440136

Eli Lilly and CompanyHealthy

Start: 2022-06-28End: 2023-03-08Updated: 2023-03-30

A Study of STAR-0215 in Healthy Adult Participants

CompletedNCT05477160

Astria Therapeutics, Inc.Hereditary Angioedema

Start: 2022-07-27End: 2023-11-17Updated: 2024-01-11

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

Active, not recruitingNCT07116889

Generate BiomedicinesAsthma, COPD (Chronic Obstructive Pulmonary Disease)

Start: 2023-12-12End: 2027-05-31Target: 156Updated: 2025-11-05

Phase 3

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

CompletedNCT03782376

Janssen-Cilag Ltd.Crohn Disease

Start: 2018-12-20End: 2023-01-10Updated: 2025-04-29

Related Papers

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.

2025-12-01

Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults.

2025-03-282 citations

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial

The Journal of Infectious Diseases2015-03-1986 citations